2. 1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements
on our current expectations and projections about future events. Our actual results could differ materially from those
discussed in, or implied by, these forward-looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"
"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Forward-looking statements
include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and
Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax
rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from
time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities
Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
2
Forward Looking Statements
4. 3
4
Advantages of Oral Thin Film Delivery
We are focused on areas where oral films
are particularly well-suited:
Develop and commercialize products that provide therapeutic advantages to patients
leveraging oral films, such as:
โข Reduced side effects
โข Improved bio-availability
โข Response time versus existing drugs
โข Lifecycle management
โข Repurpose existing drugs for new indications using oral films
โข โFirst-to-fileโ Generic drugs where high technology barriers to
entry exist in reproducing branded films
5. 5
Clearly Defined BD Strategy
Balancing Risks and Opportunities for an Optimized Portfolio
Overall
Risk
Time to MarketSlow Fast
Low
High
Drug Repurposing
Patient Benefits
Lifecycle Mgmt
FTF Generics
IntelGenx Future Focus
Deal Value
Low
Medium
High
6. 5
A Robust Product Pipeline
to Address Significant Market Opportunities
6
7. 6
7
โข High dose version of Wellbutrin XLยฎ
โข Only approved, once-daily, bupropion HCl 450mg dose
in a single tablet
โข Launched commercially October 2013 in partnership
with Edgemont Pharmaceuticals
โข Sold US revenue to SWK Holdings for US$6M
โข Development cost $2.5M, total revenue $15M = 6-fold
ROI
โข Non-dilutive source of funding, will be used to advance
film projects
Successful Monetization of First
In-House Development
8. 7
8
โข Licensing and development agreements entered for
four generic products
โข IntelGenx granted Chemo exclusive worldwide license
to commercialize two generic tablets and U.S. license
for two other generic oral films
โข IntelGenx to receive upfront, milestone, R&D
revenues and share of profits โ total value of 7 digits
โข Combined total market of four products is over $7B
โข Chemo making a strategic move into novel drug
delivery products with IntelGenx as its partner
โข Partnership could result in numerous future product
agreements
Strategic Partnership with Chemo Group
About Chemo Group:
โข Founded in 1978
โข 5,000 employees
โข Head office in Spain
โข Revenues of $1.2B annually
โข Markets over 300 products
โข Operating in over 40 countries
โข 20 state-of-the-art facilities
โข 9 specialized R&D centers
9. 8
For Migraines
Leverages VersaFilmโข Technology
9
โข European Mktg Approval โ November 2015
โข Co-development partnership with RedHill Biopharma
โข Definitive agreement signed July 2016 with
Grupo Juste for Spain & additional territories
โข Definitive agreement signed Dec 2016 with
Pharmatronic for South Korea
โข Actively pursuing several opportunities to open new
markets - negotiations with future commercialization
partners ongoing
โข Planned USA submission to FDA Q1/2017
โข Expected USA launch Q3/2017
10. 9
For Erectile Dysfunction
โข Accelerates our partnering of this product
for commercializing Tadalafil in the U.S.
โข Containing tadalafil (Cialisยฎ - Eli Lilly),
a leading molecule in the ED market
โข Demonstrated bioequivalence to Cialisยฎ
โข Orally disintegrating films without need
for water provide unprecedented patient
convenience and a discrete dosing
alternative
โข 505(b)(2) USA NDA submission in
Q2/2017
โข Expected USA launch Q2/2018
10
IntelGenx secured license from Lilly for
Tadalfil ED dosing patent โ166
11. 10
For Schizophrenia &
Bipolar 1 Disorder
11
โข The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilmโข, for treatment of
schizophrenia & bipolar 1 disorder
โข Fast-acting loxapine oral dosage โ to
treat acute agitation and anxiety in non-
institutionalized patients with
schizophrenia & bipolar 1 disorder
โข Reduces risk of pulmonary problems
and potential risk of violence and injury to
patients and others
โข Formulation optimization stage โ results
expected Q2 2017
12. 11
For Mild Cognitive Impairment
12
โข IntelGenx is repurposing Montelukast
for the treatment of MCI by leveraging
its VersaFilmโข technology
โข The drug is known and approved for a
completely different indication (asthma)
Global Sales for AD by Patients Category
(Global Data, 2013)
13. 12
2
13
Clinical Data
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0.00 5.00 10.00 15.00 20.00 25.00 30.00
Montelukastconcentration(ng/mL)
Time (hrs)
Montelukast Avg Plasma Profile
Test buccal film 10mg
Ref tablet 10mg
โข Phase 1 clinical study in human successfully completed
โข Significantly increased bioavailability after administration of VersaFilm compared to
commercial tablet
โข Drug crosses blood/brain barrier when given as film
โข Phase II-a study (proof of concept) to commence Q1/2017
โข First efficacy data in humans available Q4/2017
โข Several Pharma companies have expressed strong interest
Before
MMSE 13:
moderate to severe
dementia
MMSE 22:
mild dementia
After 2 Months of
Montelukast
14. 13
14
Construction of Manufacturing Facility Completed
โข 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
โข Facility to be fully operational by Q1 2017
โข High capacity manufacturing and
packaging equipment
โข Lower costs, controls quality
and de-risks investment
for new products
GROSS MARGINS of 40% PLUS
We have built a state-of-the-art
oral film development and manufacturing facility
15. 14
Strengthened Management Team
Over 20 Employees, including 7 with Ph.D.โs
Andre Godin, CPA, CA
Executive VP, CFO
โข 25+ years biotech/pharma
industry experience
โข Member of the Canadian
Chartered Professional
Accountants and the
Canadian Institute of
Chartered Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
โข Co-inventor of IntelGenx
Trilayer Technology
โข 15 years experience in
product development and
technology transfer
Edward Miller, B. Comm
Director, Investor Relations
โข 15 years experience in
investor relations
โข 10 + years experience in
pharmaceutical / biotech
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
โข Co-Founder of Listerine
breath strips
โข 30+ years drug delivery /
pharma experience
โข Holds over 40 patents in drug
delivery and numerous
scientific publications
15
Dana Matzen, Ph.D.
VP, Business & Corporate
Development
โข 15 years experience in
pharmaceutical product
licensing
โข Prev. Director, BD at Paladin
โข Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
โข 20+ years experience in
pharmaceutical
manufacturing, quality
management, product
development
โข Held executive positions with
several Canadian and US
companies
16. 15
16
The IntelGenx Advantage
1. History
โข Dr. Zerbe a pioneer with over 30 plus years in oral films
2. Formulation Team
โข Strong in applying biopharmaceutical aspects to formulation development
โข Top quality scientists: highly creative, focused on problem solving & innovative approaches
โข Experienced in developing films for oral (GI), sublingual & buccal absorption
3. Clearly Defined Corporate Strategy And Business Model
โข Focus on drug repurposing, lifecycle management, patient benefits, and FTF
โข Provider of comprehensive pharmaceutical services to industry partners
4. Competitive Manufacturing Capabilities
โข First in Canada
โข New state-of-the-art manufacturing facility
โข Offer one-stop-shopping to our partners with lean operations keeping costs down
โข Customized manufacturing equipment
19. 18
Net Comprehensive Income & Adjusted EBITDA ($M)
-1.5
0.6
0.8
-2.2
-0.9
1.3
1.7
-1.6
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
First 9 mths 2016 First 9 mths 2015 2015 Full Year 2014 Full Year
Net Income Adjusted EBITDA
$M
Financial Performance
19
21. 20
21
Solid Platform for Growth
Significant Market Potential
โข New manufacturing facility will offer many competitive advantages
โข Strengthened management team to accelerate execution of business plan
โข Implemented product sourcing strategy to identify high-value product opportunities
โข Building strategic partnerships with relevant partners in the pharmaceutical industry
Solid Platform for Growth
